XBiotech Inc. (XBIT): Price and Financial Metrics

XBiotech Inc. (XBIT): $3.35

0.09 (+2.76%)

POWR Rating

Component Grades













Add XBIT to Watchlist
Sign Up

Industry: Biotech



in industry


  • XBIT scores best on the Growth dimension, with a Growth rank ahead of 68.25% of US stocks.
  • The strongest trend for XBIT is in Value, which has been heading down over the past 179 days.
  • XBIT ranks lowest in Momentum; there it ranks in the 4th percentile.

XBIT Stock Summary

  • The ratio of debt to operating expenses for XBIOTECH INC is higher than it is for about only 0.44% of US stocks.
  • XBIT's price/sales ratio is 25.43; that's higher than the P/S ratio of 94.95% of US stocks.
  • Revenue growth over the past 12 months for XBIOTECH INC comes in at -78.2%, a number that bests only 2.05% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to XBIT, based on their financial statements, market capitalization, and price volatility, are NRIX, NTLA, RVMD, RNA, and INBX.
  • XBIT's SEC filings can be seen here. And to visit XBIOTECH INC's official web site, go to www.xbiotech.com.

XBIT Valuation Summary

  • XBIT's price/sales ratio is 26; this is 453.19% higher than that of the median Healthcare stock.
  • XBIT's price/sales ratio has moved NA NA over the prior 96 months.

Below are key valuation metrics over time for XBIT.

Stock Date P/S P/B P/E EV/EBIT
XBIT 2023-03-17 26.0 0.4 -3.2 1.6
XBIT 2023-03-16 26.0 0.4 -3.2 1.6
XBIT 2023-03-15 25.7 0.4 -3.1 1.6
XBIT 2023-03-14 12.1 0.4 -2.7 3.1
XBIT 2023-03-13 12.3 0.4 -2.8 3.1
XBIT 2023-03-10 12.4 0.4 -2.8 3.1

XBIT Growth Metrics

    The year over year cash and equivalents growth rate now stands at -3.36%.
  • Its 2 year price growth rate is now at -58.56%.
  • Its 5 year price growth rate is now at 62.32%.
XBIT's revenue has moved up $8,210,000 over the prior 67 months.

The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.21 -19.286 -36.164
2022-06-30 11.049 -16.661 -26.767
2022-03-31 14.044 62.513 -20.241
2021-12-31 18.394 69.445 -17.414
2021-09-30 19.163 70.813 -12.785
2021-06-30 25.193 81.698 -12.05

XBIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
  • XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.

The table below shows XBIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.391 -0.195
2021-03-31 0.102 0.248 -0.138
2020-12-31 0.124 0.215 -0.116
2020-09-30 0.082 0.166 7.794
2020-06-30 0.070 0.188 10.040
2020-03-31 0.039 0.237 14.665

XBIT Stock Price Chart Interactive Chart >

Price chart for XBIT

XBIT Price/Volume Stats

Current price $3.35 52-week high $9.58
Prev. close $3.26 52-week low $3.00
Day low $3.25 Volume 12,300
Day high $3.49 Avg. volume 32,902
50-day MA $3.79 Dividend yield N/A
200-day MA $4.13 Market Cap 101.97M

XBiotech Inc. (XBIT) Company Bio

XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.

XBIT Latest News Stream

Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream

Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable

Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So take...

Yahoo | February 15, 2023

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | January 19, 2023

XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

XBiotech ( NASDAQ:XBIT ) Third Quarter 2022 Results Key Financial Results Net loss: US$12.7m (loss widened by 288% from...

Yahoo | November 11, 2022

Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company

If you want to know who really controls XBiotech Inc. ( NASDAQ:XBIT ), then you'll have to look at the makeup of its...

Yahoo | October 31, 2022

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech’s candidate cancer treatment i

Yahoo | October 13, 2022

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo -4.29%
3-mo 8.77%
6-mo -9.95%
1-year -63.98%
3-year -65.50%
5-year -29.47%
YTD -4.56%
2022 -68.46%
2021 -28.88%
2020 -16.15%
2019 267.42%
2018 28.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8219 seconds.